Literature DB >> 9685105

Analysis of health-related quality of life and muscle impairment in individuals with amyotrophic lateral sclerosis using the medical outcome survey and the Tufts Quantitative Neuromuscular Exam.

R K Shields1, J L Ruhland, M A Ross, M M Saehler, K B Smith, M L Heffner.   

Abstract

OBJECTIVE: The Tufts Quantitative Neuromuscular Exam (TQNE) is commonly used to assess the rate of disease progression in individuals with amyotrophic lateral sclerosis (ALS). The Medical Outcome Study Short Form (SF-36) is a general method to assess health-related quality of life (HRQL). This study examined the relationship between the TQNE and SF-36, established the reliability and responsiveness of each, and contrasted the HRQL between individuals with ALS and the general population.
DESIGN: Subjects (31) completed the SF-36 and TQNE within 1 week to determine reliability. Subjects (17) also completed both the TQNE and SF-36 each month for 1 year after diagnosis of ALS to establish the relationship between the two assessment tools.
SETTING: A primary care university teaching hospital. PATIENTS: Thirty-one subjects with an age range of 27 to 76 years (mean 59.1, SD 10.32), recently diagnosed with ALS.
RESULTS: Each test was highly reliable and responsive. The intraclass correlations (2, 1) were consistently higher for the TQNE (.93 to .98) than for the SF-36 (.57 to .90). Changes in physical function were correlated to changes in lower extremity force megascores (.48).
CONCLUSION: Both the TQNE and the SF-36 are reliable and responsive and appear important in characterization of patient status after ALS is diagnosed.

Entities:  

Mesh:

Year:  1998        PMID: 9685105     DOI: 10.1016/s0003-9993(98)90370-7

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  8 in total

1.  On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation.

Authors:  C B Terwee; F W Dekker; W M Wiersinga; M F Prummel; P M M Bossuyt
Journal:  Qual Life Res       Date:  2003-06       Impact factor: 4.147

2.  Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40.

Authors:  C Jenkinson; R Fitzpatrick; C Brennan; M Bromberg; M Swash
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

3.  Influence of age on dynamic position sense: evidence using a sequential movement task.

Authors:  Sangeetha Madhavan; Richard K Shields
Journal:  Exp Brain Res       Date:  2005-03-18       Impact factor: 1.972

4.  Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.

Authors:  H L D Horemans; F Nollet; A Beelen; G Drost; D F Stegeman; M J Zwarts; J B J Bussmann; M de Visser; G J Lankhorst
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

5.  Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis.

Authors:  C Green; G Kiebert; C Murphy; J D Mitchell; M O'Brien; A Burrell; P N Leigh
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

6.  Patients with ALS show highly correlated progression rates in left and right limb muscles.

Authors:  David J Rushton; Patricia L Andres; Peggy Allred; Robert H Baloh; Clive N Svendsen
Journal:  Neurology       Date:  2017-06-09       Impact factor: 9.910

7.  Effect of muscle strengthening exercise and time since onset in patients with amyotrophic lateral sclerosis: A 2-patient case series study.

Authors:  Naoki Kato; Goichi Hashida; Kuni Konaka
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

8.  Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease.

Authors:  Jaap N E Bakers; Leonard H van den Berg; Toju G Ajeks; Maxine J Holleman; Jill Verhoeven; Anita Beelen; Johanna M A Visser-Meily; Ruben P A van Eijk
Journal:  J Neurol       Date:  2020-12-23       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.